Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Hughes, Richard A C ^a   Lunn, Michael P T ^a   Frost, Chris ^b   van Schaik, Ivo N ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADVERSE OUTCOME; ARTICLE; CLINICAL OUTCOME; CONTRACEPTIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; KINESIOTHERAPY; LIVER FUNCTION; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW;

EID: 85044383532     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010369     Document Type: Article

References (29)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 1991;41(5):617-8. [PUBMED: 2027473]
2. Allen D, Lunn MP, Niermeijer J, Nobile-Orazio E. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005376.pub2; PUBMED: 17253554]
3. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20(6):828. [PUBMED: 2728057]
4. Becker LA, Oxman AD. Chapter 22: Overview of reviews. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org, 2011.
5. Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, et al.Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Effectiveness and Resource Allocation 2010;8:14-23. [MEDLINE: 12835]
6. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001797.pub2; PUBMED: 19160200]
7. Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows 2008.
8. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. Journal of Neurology, Neurosurgery and Psychiatry 2006;77(8):973-6. [PUBMED: 16574730 ]
9. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [PUBMED: 18436948]
10. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. The Lancet 1978;2(8093):750-3. [PUBMED: 80682]
11. Hughes R, Bensa S, Willison HJ, van den Bergh P, Comi G, Illa I, et al.Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 2001;50(2):195-201. [PUBMED: 11506402]
12. Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011;25(6):491-502. [PUBMED: 21649449]
13. Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle and Nerve 1991;14(11):1103-9. [PUBMED: 1745285]
14. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002827.pub3; PUBMED: 22592686]
15. Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD003280.pub3; PUBMED: 21069674]
16. Mahdi-Rogers M. The Epidemiology and Treatment of Chronic Acquired Neuropathies [MD Thesis]. London, UK: London University, 2010.
17. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Seminars in Oncology 2002;29(1 Suppl 2):2-9. [PUBMED: 11842383]
18. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD002062; PUBMED: 11687011]
19. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD003906.pub2; PUBMED: 15266507]
20. Merkies ISJ, Schmitz PIM, Van der M, FGA, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology 2000;54(4):943-9. [PUBMED: 10690990]
21. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. Journal of Neurology Neurosurgery and Psychiatry 2002;72(5):596-601. [PUBMED: 11971045]
22. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2; PUBMED: 17943857]
23. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al.Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [MEDLINE: 13561]
24. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al.AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. Journal of Clinical Epidemiology 2009;62(10):1013-20. [MEDLINE: 13569]
25. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurology 2010;9(4):402-12. [PUBMED: 20298964]
26. Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al.European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. European Journal of Neurology 2010;17(3):356-63. [PUBMED: 20456730]
27. White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003904.pub2; PUBMED: 15495069]
28. White CM, van Doorn PA, Garssen MPJ, Stockley RC. Interventions for fatigue in peripheral neuropathy. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008146; EMBASE: 2010193005]
29. White IR. Multivariate random-effects meta-regression: updates to mvmeta. The Stata Journal 2011;11(2):255-70.